Stay updated on GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference3%

- Check27 days agoChange DetectedUpdated the page to reflect a new version (v3.1.0) and removed the old version tag (v3.0.2).SummaryDifference0.1%

- Check41 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2, signaling an updated release. The 'Back to Top' link has been removed, a minor UI change.SummaryDifference0.2%

- Check48 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.2%

- Check55 days agoChange DetectedThe web page has undergone significant updates, including the addition of specific medical terms related to lung diseases and the facility name and location, while removing various location-related terms and some medical classifications.SummaryDifference2%

- Check70 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.